002030 达安基因
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-1.701-9.913-11.0401.03758.034
总资产报酬率 ROA (%)-1.434-8.231-8.9840.81243.137
投入资产回报率 ROIC (%)-1.637-9.516-10.4920.99154.967

边际利润分析
销售毛利率 (%)33.81432.40137.54750.46772.842
营业利润率 (%)-41.270-99.431-125.15510.29952.542
息税前利润/营业总收入 (%)-42.361-104.685-133.2003.28551.534
净利润/营业总收入 (%)-37.967-103.017-110.0926.07445.056

收益指标分析
经营活动净收益/利润总额(%)80.74439.26819.14241.799108.478
价值变动净收益/利润总额(%)61.996-7.13440.104360.6295.594
营业外收支净额/利润总额(%)-2.0320.4800.332-7.122-0.163

偿债能力分析
流动比率 (X)2.9612.8232.9233.0852.954
速动比率 (X)2.8052.6762.7702.9462.829
资产负债率 (%)12.56813.46314.97216.88921.286
带息债务/全部投入资本 (%)2.0921.9422.4884.1502.072
股东权益/带息债务 (%)4,602.1834,953.7513,850.3552,273.6244,656.178
股东权益/负债合计 (%)674.261622.998549.549477.214359.775
利息保障倍数 (X)22.14521.92717.462-0.519-55.909

营运能力分析
应收账款周转天数 (天)396.099475.119698.914933.39894.518
存货周转天数 (天)120.836121.527147.901187.44447.499